Follistatin 344 2mg/vial 1 Vial by Knoll Pharmaceuticals

Usage

1. Inspect the sealed Knoll Pharmaceuticals vial for label integrity and confirm the lot number matches your batch documentation before proceeding.
2. Allow the vial to equilibrate to room temperature (approximately 15–20 minutes) before reconstitution to reduce thermal shock to the lyophilised cake.
3. Draw the required volume of bacteriostatic water into a U-100 insulin syringe (27–31 G recommended); inject slowly against the inner glass wall — not directly onto the peptide cake — to preserve follistatin-344 structure.
4. Swirl the vial gently in a circular motion until the powder is fully dissolved; a clear, colourless solution indicates complete reconstitution. Do not shake or vortex.
5. Time your injection to fall within the 2–4 hour post-training window where MGF expression is highest, thereby aligning Follistatin-344's myostatin-clearance action with peak mechano-responsive satellite-cell signalling.
6. Store the reconstituted vial at 2–8 °C, protected from light; discard any unused solution after 28 days or if the solution becomes cloudy or particulate.

Warnings

Frequently asked questions

What is Mechano Growth Factor and how does it relate to Follistatin-344?

Mechano Growth Factor (MGF) is a splice variant of IGF-1 produced locally in muscle fibres in response to mechanical loading or micro-damage — it is among the earliest signals that recruit satellite cells for repair. Follistatin-344 complements MGF activity by neutralising myostatin, the principal inhibitory ligand that limits how far that satellite-cell recruitment can proceed, creating a broader anabolic window for the MGF signal to act within.

When is the optimal time to administer Follistatin-344 relative to a resistance training session?

Research into MGF kinetics shows that local IGF-1Ec expression peaks within 2–4 hours after mechanical loading (Yang & Goldspink, 2002). Administering Follistatin-344 in the peri-workout period — typically within this 2–4 hour window — aligns the myostatin-clearance action with the phase of highest endogenous MGF activity, maximising the overlap between the inhibitory ligand blockade and the mitogenic proliferation signal.

What does PEGylation do to MGF, and why does Follistatin-344 operate on a different level?

PEGylation conjugates polyethylene glycol chains to MGF, extending its plasma half-life from under ten minutes to approximately 15–18 hours, allowing systemic distribution rather than only local action. Follistatin-344 does not extend any growth factor's half-life; instead it binds and sequesters myostatin (Kd ≈ 0.1 nM, cell-free assay data) to reduce the inhibitory pressure that both endogenous and exogenous MGF must overcome — a mechanistically distinct and complementary intervention.

How should Follistatin-344 2mg/vial be reconstituted and stored after opening?

Reconstitute with bacteriostatic water: inject the water slowly against the inner glass wall to avoid disrupting the lyophilised cake, then swirl gently — never vortex. At 2 mg/vial, this is the highest single-vial concentration in the current group; once reconstituted, store at 2–8 °C and use within 28 days. Discard if the solution shows particulate matter or colour change. Keep the unreconstituted vial at −20 °C for long-term storage.

Can insulin syringes be used to dose Follistatin-344, and what volume is typical per injection?

Yes — U-100 insulin syringes (0.3 mL or 0.5 mL barrel) are the standard tool for subcutaneous or intramuscular peptide administration due to their fine gauge (27–31 G) and precise graduation. If the 2 mg vial is reconstituted in 2 mL of bacteriostatic water, each 0.1 mL drawn equals 100 mcg of Follistatin-344, making dose calculation straightforward. Always confirm your target dose with a qualified researcher or clinician before proceeding. (2) angle_used

Manufacturer

Within Knoll Pharmaceuticals' lyophilised peptide catalogue, the Follistatin-344 2 mg/vial line is subject to a two-gate release framework whose checkpoints are analytically independent and sequentially mandatory. Gate one consists of HPLC characterisation of the bulk Follistatin-344 API: the chromatographic profile is cross-referenced against a defined reference standard to confirm both peptide identity and purity, and no batch advances to fill-and-finish operations until the chromatographic result meets the specified threshold. Gate two is a LAL (Limulus Amebocyte Lysate) endotoxin quantification assay performed on the same API lot — a critical safety check for any parenteral peptide preparation, given that endotoxin contamination is undetectable by visual inspection alone. Vials that clear both gates are assigned a lot-specific documentation record linking the analytical results to the finished product, giving researchers a traceable data trail from API acceptance through to the sealed vial they receive.